SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY

被引：5
|
作者：
Matucci-Cerinic, M. [1 ]
Schulze-Koops, H. [2 ]
Buch, M. [3 ]
Kavanaugh, A. [4 ]
Allanore, Y. [5 ]
Kucharz, E. J. [6 ]
Babic, G. [7 ]
机构：
[1] Univ Florence, Florence, Italy
[2] Ludwig Maximillans Univ, Munich, Germany
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[5] Paris Descartes Univ, Cochin Hosp, Paris, France
[6] Med Univ Silesia, Katowice, Poland
[7] Hexal AG, Holzkirchen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0129
引用
收藏
页码：609 / 609
页数：1
相关论文
共 50 条
  • [21] Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
    Girolomoni, G.
    Feldman, S. R.
    Emery, P.
    Ghil, J.
    Keum, J. W.
    Cheong, S. Y.
    Hong, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : E215 - E216
  • [22] The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
    Griffiths, C. E. M.
    Thaci, D.
    Gerdes, S.
    Arenberger, P.
    Pulka, G.
    Kingo, K.
    Weglowska, J.
    Hattebuhr, N.
    Poetzl, J.
    Woehling, H.
    Wuerth, G.
    Afonso, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (04) : 928 - 938
  • [23] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Baranauskaite, Asta
    Tseluyko, Vira
    Zhdan, Vyacheslav
    Stasiuk, Barbara
    Milasiene, Roma
    Barrera Rodriguez, Aaron Alejandro
    Cheong, Soo Yeon
    Ghil, Jeehoon
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [24] A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS)
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Baranauskaite, A.
    Tseluyko, V.
    Zhdan, V.
    Stasiuk, B.
    Milasiene, R.
    Rodriguez, A. A. Barrera
    Cheong, S. Y.
    Ghil, J.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 467 - 468
  • [25] OUTCOMES OF THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE IN RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS RECEIVING GP2015 (ETANERCEPT BIOSIMILAR) IN A REAL-WORLD STUDY: FINAL RESULTS FROM COMPACT STUDY
    Schmalzing, M.
    Askari, A.
    Sheeran, T.
    Jathanakodi, S.
    Both, C.
    Kellner, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1397 - 1397
  • [26] The comparison of efficacy and safety between etanercept (ETN) plus methotrexate (MTX) combination therapy and ETN monotherapy in MTX-refractory Japanese patients with rheumatoid arthritis: 52-week clinical results from the JESMR study
    Kameda, Hideto
    Ueki, Yukitaka
    Saito, Kazuyoshi
    Nagaoka, Shouhei
    Hidaka, Toshihiko
    Atsumi, Tatsuya
    Tsukano, Michishi
    Kasama, Tsuyoshi
    Shiozawa, Shunichi
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S531 - S531
  • [27] Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
    Burmester, Gerd
    Trefler, Jakub
    Racewicz, Artur
    Jaworski, Janusz
    Zielinska, Agnieszka
    Krogulec, Marek
    Jeka, Slawomir
    Wojciechowski, Rafal
    Kolossa, Katarzyna
    Dudek, Anna
    Krajewska-Wlodarczyk, Magdalena
    Hrycaj, Pawel
    Klimiuk, Piotr Adrian
    Kim, SungHyun
    Suh, JeeHye
    Yang, Goeun
    Kim, Yunah
    Jung, YooBin
    Hong, Jiwoo
    Smolen, Josef
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1017 - 1019
  • [28] 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
    Emery, Paul
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Baranauskaite, Asta
    Tseluyko, Vira
    Zhdan, Vyacheslav M.
    Stasiuk, Barbara
    Milasiene, Roma
    Barrera Rodriguez, Aaron Alejandro
    Cheong, Soo Yeon
    Ghil, Jeehoon
    RHEUMATOLOGY, 2017, 56 (12) : 2093 - 2101
  • [29] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [30] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    国际皮肤性病学杂志（英文）, 2022, 05 (04)
12345